Immunocore (IMCR) Q2 2026 earnings review
KIMMTRAK Defies Moderation, But a $120M Rebate Bill Looms
Immunocore delivered a surprisingly strong quarter, with KIMMTRAK sales accelerating to $115.9M (+18% YoY), defying management's previous guidance of growth moderation. The commercial engine is operating efficiently, keeping the company flirting with breakeven (Net Loss of just $0.8M). However, the cash flow story will take a hit next quarter, as management flagged a massive $120M payment for sales-related rebates in H2 2026. Ultimately, while commercial execution is stellar, the stock's future hinges entirely on the impending Phase 3 TEBE-AM data readout for cutaneous melanoma expected later this year.
🐂 Bull Case
KIMMTRAK continues to exceed expectations. US sales grew 17% YoY and international regions grew 21% YoY, driven by a best-in-class 14-month duration of therapy and newly presented 5-year overall survival data that cements its standard-of-care moat.
The Phase 3 TEBE-AM trial is nearing its 540-patient enrollment target. If successful, this expands KIMMTRAK into second-line cutaneous melanoma—a market of up to 4,000 patients, drastically larger than the current uveal melanoma indication.
🐻 Bear Case
The company expects to pay $120M in sales-related rebate accruals in H2 2026. This is a severe step-up from the ~$65M paid in H2 2025 and will materially draw down the $880M cash balance.
Immunocore's valuation is heavily levered to the TEBE-AM trial. If it fails to show a statistically significant overall survival benefit, the company falls back to being a single-indication commercial entity with heavy Phase 3 R&D costs weighing on profitability.
⚖️ Verdict: ⚪
Neutral. The commercial outperformance is fantastic, but the looming $120M cash drain and the extreme binary risk of the upcoming TEBE-AM readout make this a 'wait and see' situation for conservative investors.
Key Themes
KIMMTRAK Revenue Accelerating Despite Warnings
For several quarters, management guided that KIMMTRAK growth would moderate as it saturated the uveal melanoma market. Instead, Q2 2026 sales accelerated to 18% YoY growth ($115.9M) compared to 13.6% growth in Q1 2026. This resilience is fueled by a 14-month mean duration of treatment in the US and expanding international demand, proving the drug's real-world utility exceeds initial clinical trial timelines.
Escalating Rebate Accruals Threaten Cash Flow
Management casually noted in the release that they expect to pay approximately $120 million in sales-related rebate accruals in H2 2026. This is a massive jump from the ~$65 million they paid in H2 2025. While the company holds $880 million in cash, this single payout represents nearly 14% of their total cash pile and highlights the severe gross-to-net pricing pressures they face internationally.
SG&A Discipline Funds R&D Expansion
Immunocore continues to execute a masterclass in cost control on the commercial side. SG&A has remained remarkably stable around $38-44M for six straight quarters. This discipline allows the company to fund a heavy Phase 3 pipeline (TEBE-AM, ATOM, PRISM-MEL-301) without burning excessive cash. R&D jumped to $73.9M in Q2, but the flat commercial spend keeps the bottom line near breakeven.
PRAME Franchise Advancing in Frontline Melanoma
The Phase 3 PRISM-MEL-301 trial evaluating brenetafusp in first-line advanced cutaneous melanoma is progressing smoothly. The company confirmed the 160 mcg dose based on promising Phase 1/2 ASCO data that showed a 17% response rate and 67% disease control rate in heavily pretreated patients. Successfully penetrating the frontline setting (up to 10,000 addressable patients) would transform Immunocore into a multi-blockbuster oncology company.
TEBE-AM Binary Risk and Trial Design Scrutiny
The entire near-term narrative relies on the Phase 3 TEBE-AM trial reading out positive overall survival data as early as late 2026. Historically, analysts have scrutinized the trial's design—specifically whether the combination arm can prove KIMMTRAK's contribution if the monotherapy arm fails. Any regulatory pushback or failure to beat the control arm's survival benchmark (assumed ~12-15 months) would be devastating to the stock.
Other KPIs
Stable. The company is effectively hovering around breakeven, a dramatic improvement from a $10.3M loss in the same quarter last year. This is driven by high margin KIMMTRAK revenue scaling slightly faster than combined operating expenses.
Stable. Up from $864.2M at the end of 2025, showing that despite running three massive Phase 3 trials, the commercial cash generation and interest income are fully funding the operation. However, the impending $120M rebate payment will dent this next quarter.
Guidance
Accelerating negative impact. This is an explicit cash outflow expectation for the second half of the year, significantly higher than the ~$65M paid in the same period last year. It reflects accumulated gross-to-net true-ups, largely from European markets.
Stable timeline. The company reiterated that data from the highly anticipated cutaneous melanoma trial could arrive as early as the end of 2026, as enrollment nears the 540-patient target.
Key Questions
Rebate Dynamics
The expected H2 rebate payment has nearly doubled to $120M compared to last year. Is this a one-time catch-up from specific country negotiations, or does this represent a structural step-up in gross-to-net deductions moving forward?
TEBE-AM Commercial Readiness
Assuming a positive TEBE-AM readout in late 2026, how quickly can the current commercial infrastructure transition to the much larger cutaneous melanoma market without requiring a massive SG&A build-out?
PRAME and HIV Prioritization
With brenetafusp moving forward in Phase 3 and promising early HIV data, how will you allocate R&D capital if both the HLE PRAME variant and the HIV program show strong signals later this year? Will you need to partner?